Nearly a decade into the race to arm pulmonologists with interventional tools to treat emphysema, no clear winner is emerging. Emphasys, which had led the pack in developing a bronchial valve, hit a potential roadblock at the FDA. The question is whether competitors can fill the gap.
Tom Salemi
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
